Arcutis Biotherapeutics Newsroom

TD Cowen Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $20

Moomoo NewsNov 11 08:31 ET

TD Cowen Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $20

Moomoo NewsNov 7 08:32 ET

Needham Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $18

Moomoo NewsNov 7 07:31 ET

Arcutis Biotherapeutics Price Target Maintained With a $18.00/Share by Needham

Dow JonesNov 7 06:34 ET

Morgan Stanley Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $19

Moomoo NewsNov 7 06:33 ET

TD Cowen Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $20

Moomoo NewsNov 6 23:32 ET

Arcutis Biotherapeutics: Strong Commercial Execution and Strategic Growth Initiatives Justify Buy Rating

TipRanksNov 6 22:47 ET

Mizuho Securities Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating

Moomoo NewsOct 25 12:31 ET

Mizuho Securities Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating

Moomoo NewsOct 23 05:31 ET

Buy Rating Reaffirmed for Arcutis Biotherapeutics Amid Temporary Challenges and Strong Zoryve Sales Forecast

TipRanksOct 23 04:37 ET

Morgan Stanley Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $19

Moomoo NewsOct 22 09:31 ET

Mizuho Securities Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Announces Target Price $19

Moomoo NewsOct 3 20:32 ET

Mizuho Securities Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating

Moomoo NewsSep 27 14:31 ET

Analysts Offer Insights on Healthcare Companies: Bioxcel Therapeutics (BTAI) and Arcutis Biotherapeutics (ARQT)

TipRanksSep 25 07:53 ET

Morgan Stanley Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $19

Moomoo NewsSep 19 06:33 ET

Buy Rating Affirmed for Arcutis Biotherapeutics Amid Positive Dermatology Market Signals

TipRanksSep 19 06:19 ET

Arcutis Biotherapeutics Analyst Ratings

BenzingaAug 28 08:21 ET

Jefferies Initiates Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Announces Target Price $15

Moomoo NewsAug 28 05:31 ET

Buy Rating Initiated on Arcutis Biotherapeutics Amidst Zoryve's Market Expansion and Promising Sales Trajectory

TipRanksAug 28 04:48 ET

Mizuho Securities Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating

Moomoo NewsAug 23 11:32 ET